Great article Snouty
keeping in mind the imuno drugs discussed in that article are T cell drugs and theirfore monoclonal antibodies, it is those very same market spaces that Imugenes "disruptive" B Cell polyclonal antibodies will obtain, with an expected greater and longer lasting response and with greatly reduced auto-immune side effects.
fp
Add to My Watchlist
What is My Watchlist?
